References
1. Kaltseis J, Rainer J, De Hoog GS. Ecology of Pseudallescheria and Scedosporium species in human-dominated and natural environments and their distribution in clinical samples. Med Mycol . 2009; 47(4):398-405.
2. Rougeron A, Giraud S, Alastruey-Izquierdo A, et al. Ecology of Scedosporium Species: Present Knowledge and Future Research.Mycopathologia . 2018; 183(1):185-200.
3. Liu W, Feng RZ, Jiang HL. Scedosporium spp lung infection in immunocompetent patients: A systematic review and MOOSE-compliant meta-analysis. Medicine (Baltimore) . 2019; 98(41):e17535.
4. Heath CH, Slavin MA, Sorrell TC, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect . 2009; 15(7):689-693.
5. Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases.Med Mycol . 2009; 47(4):359-370.
6. Grenouillet F, Botterel F, Crouzet J, et al. Scedosporium prolificans: an emerging pathogen in France?. Med Mycol . 2009; 47(4):343-350.
7. Tintelnot K, Just-Nübling G, Horré R, et al. A review of German Scedosporium prolificans cases from 1993 to 2007. Med Mycol . 2009; 47(4):351-358.
8. Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Med Mycol . 2018; 56(suppl_1):102-125.
9. Lamaris GA, Chamilos G, Lewis RE, et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006.Clin Infect Dis . 2006; 43(12):1580-1584.
10. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect . 2004; 10(Suppl 1):48-66.
11. Cimon B, Carrère J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis . 2000; 19(1):53-56.
12. Bashir G, Shakeel S, Wani T, et al. Pulmonary pseudallescheriasis in a patient with healed tuberculosis. Mycopathologia . 2004; 158(3):289-291.
13. Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect . 2014; 20(Suppl 3):27-46.
14. Tekavec J, Mlinarić-Missoni E, Babic-Vazic V. Pulmonary tuberculosis associated with invasive pseudallescheriasis. Chest . 1997; 111(2):508-511.
15. Ogata H, Harada E, Okamoto I. Scedosporium apiospermum lung disease in a patient with nontuberculous mycobacteria. Respirol Case Rep . 2020; 9(1):e00691.
16. Rathi M, Gundlapalli S, Ramachandran R, et al. A rare case of Cytomegalovirus, Scedosporium apiospermum and Mycobacterium tuberculosis in a renal transplant recipient. BMC Infect Dis . 2014; 14:259.
17. Guarro J, Kantarcioglu AS, Horré R, et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist.Med Mycol . 2006; 44(4):295-327.
18. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, Buchanan W, Milanovich J, Sutton DA, Fothergill A, Rinaldi MG, Shea YR, Zaoutis T, Kottilil S, Walsh TJ. Infections caused by Scedosporium spp. Clin Microbiol Rev . 2008; 21(1):157-197.
19. Mir WAY, Shrestha DB, Khan Suheb MZ, et al. Scedosporium apiospermum Pneumonia in an Immunocompetent Host. Cureus . 2021; 13(8):e16891.
20. Kim JS, Choi M, Nam CH, et al. Co-infection of Scedosporium apiospermum and Mycobacterium chelonae in an immunocompetent host.J Dermatol . 2014; 41(10):922-925.
21. Sunagawa K, Yagoshi M, Suzuki A, et al. Cytological and molecular detection of Scedosporium apiospermum in a patient treated for a Mycobacterium avium complex infection. Diagn Cytopathol . 2018; 46(7):642-644.
22. Xiao W, Han P, Xu Z, et al. Pulmonary scedosporiosis in a patient with acute hematopoietic failure: Diagnosis aided by next-generation sequencing. Int J Infect Dis . 2019; 85:114-116.
23. Martin-Vicente A, Guarro J, González GM, et al. Voriconazole MICs are predictive for the outcome of experimental disseminated scedosporiosis. J Antimicrob Chemother . 2017; 72(4):1118-1122.
24. Lelièvre B, Legras P, Godon C, et al. Experimental models of disseminated scedosporiosis with cerebral involvement. J Pharmacol Exp Ther . 2013; 345(2):198-205.
25. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother . 2001; 45(7):2151-2153.
26. Solé A, García-Robles AA, Jordá C, et al. Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection. Am J Transplant . 2018; 18(2):504-509.
27. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother . 2008; 52(3):1136-1139.
28. Schwarz C, Brandt C, Melichar V, et al. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. J Cyst Fibros . 2019; 18(2):227-232.
29. Castanheira M, Duncanson FP, Diekema DJ, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother . 2012; 56(1):352-357.
30. Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. Antimicrob Agents Chemother . 2020; 64(3):e01735-19.
31. Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.Proc Natl Acad Sci U S A . 2016; 113(45):12809-12814.
32. Wiederhold NP, Patterson TF, Srinivasan A, et al. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence . 2017; 8(2):138-142.
33. Staerck C, Tabiasco J, Godon C, et al. Transcriptional profiling of Scedosporium apiospermum enzymatic antioxidant gene battery unravels the involvement of thioredoxin reductases against chemical and phagocytic cells oxidative stress. Med Mycol . 2019; 57(3):363-373.